A preoperative risk scoring system for survival prediction in clinical stage IB lung adenocarcinoma: a multicenter study

Read full text
Authors: Kotaro Murakami, Tetsuya Isaka, Takuya Nagashima, Hiroyuki Adachi, Shunsuke Shigefuku, Noritake Kikunishi, Naoko Shigeta, Yujin Kudo, Yoshihiro Miyata, Morihito Okada, N. Ikeda, Hiroyuki Ito
Cited by: 0
References: 23

Abstract

Background: Clinical stage (c-stage) IB lung adenocarcinoma (LUAD) presents variable survival outcomes, and the prognostic significance of factors such as ground-glass opacity components and positron emission tomography (PET) metrics remains unclear. Despite recent advances, no preoperative scoring model has been established to stratify risk in this subgroup. We aimed to identify preoperative prognostic factors in c-stage IB LUAD and develop a simple scoring system for predicting overall survival (OS). Methods: We retrospectively analyzed data from 245 patients with c-stage IB LUAD who underwent lobectomy at three institutions between 2010 and 2020. Cox regression analysis was performed to identify independent preoperative prognostic factors for OS. A risk score was developed by assigning points to each factor, based on the regression coefficients. Thereafter, patients were stratified into four risk groups based on their total scores. Results: Multivariate analysis identified smoking history (hazard ratio [HR]: 2.68; 95% confidence interval [CI]: 1.13-6.33; p=0.025), elevated serum carcinoembryonic antigen (CEA) levels (HR: 2.89; 95%CI: 1.42-5.91; p=0.004), and high maximum standardized uptake value (SUVmax) on PET (HR: 2.84; 95%CI: 1.16-6.98; p=0.023) as independent factors of poor prognosis. A scoring system was established by assigning one point to each factor. Patients were stratified into four risk groups: low (score 0, n=41), moderate (score 1, n=84), moderately high (score 2, n=77), and extremely high (score 3, n=43). Five-year OS rates were 100.0%, 89.3%, 74.0%, and 52.1%, respectively (p

Fields of Study & Subjects

Lung Cancer Diagnosis and Treatment Hepatocellular Carcinoma Treatment and Prognosis Cholangiocarcinoma and Gallbladder Cancer Studies

Publication details

Journal / source
Frontiers in Oncology
Volume
15
Pages
1712276–1712276
Publication date
6 January 2026
Language
EN